Eumentis Therapeutics
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
508 Dudley Rd Ste 105, Newton, Massachus...Phone Number
(617) 413-3020Website
www.eumentistx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Eumentis Therapeutics
EuMentis Therapeutics is dedicated to advancing innovative treatments for neuropsychiatric disorders, focusing on schizophrenia and Parkinson's LID. Their lead product, EM-221, is a novel PDE10A inhibitor designed to enhance cyclic nucleotide signaling and improve both positive and negative symptoms of schizophrenia. The company aims to deliver better efficacy and tolerability through targeted therapies that address the underlying mechanisms of these conditions. With a robust pipeline, EuMentis is committed to improving the quality of life for patients affected by various CNS disorders.Explore more
Eumentis Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Eumentis Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Eumentis Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Eumentis Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Eumentis Therapeutics has new funding data
Click to see if Eumentis Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Eumentis Therapeutics
Check if Eumentis Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Eumentis Therapeutics is spiking on competitors!
Eumentis Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Eumentis Therapeutics
Compare insights from companies similar to Eumentis Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Eumentis Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Eumentis Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Eumentis Therapeutics.
Eumentis Therapeutics financials insights
Gather financial insights about Eumentis Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$3.9M
Eumentis Therapeutics Tech Stack
A closer look at the technologies used by Eumentis Therapeutics
Eumentis Therapeutics News & Media
EuMentis Therapeutics' CMO Randall Marshall to Present on its novel PDE10A inhibitor for ...
Dr. Marshall's Presentation on Friday May 31, 2024EuMentis Therapeutics’ Chief Medical Office Randall Marshall, MD to Give Keynote Presentation at Autism Parenting Summit
Presentation on May 19, 2024 at 10:30am edt NEWTON CENTER, MA, UNITED STATES, May 15, 2024 /EINPresswire.com/ -- EuMentis Therapeutics’ Chief Medical Office Randall Marshall MD to Give Keynote Presentation at Autism Parenting Summit EuMentis …EuMentis Therapeutics Inc. Announces the First Closing of a Targeted $40M Series B Financing to Advance Novel Therapeutics to Treat Autism Spectrum Disorder, Tourette Syndrome and Traumatic Brain Injury
BOSTON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- EuMentis Therapeutics Inc. (“EuMentis”), a privately held biopharmaceutical company developing novel therapeutics for the treatment of neuropsychiatric and neurodevelopmental disorders, including its lead clinical-stage programs for ASD and TS, today announced the closing of $20 million of a targeted $40 million Series B financing from a private family office. EuMentis is in active discussion with other investors to complete its Series B round.EuMentis Therapeutics Plans to Initiate Phase 2 study of EM-221, a PDE10A Inhibitor, for Treatment of Tourette Syndrome
Eumentis is Developing Novel Neurocircuit Selective Medicines to Treat Childhood Neurodevelopmental Disorders NEWTON, MASSACHUSETTS, UNITED STATES, March 24, 2022 /EINPresswire.com/ -- EuMentis Therapeutics, Inc. (“EuMentis” or the “Company”), a …
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Eumentis Therapeutics
Sign Up For FreeTo access detailed company insights
EuMentis Therapeutics is dedicated to advancing innovative treatments for neuropsychiatric disorders, focusing on schizophrenia and Parkinson's LID. Their lead product, EM-221, is a novel PDE10A inhibitor designed to enhance cyclic nucleotide signaling and improve both positive and negative symptoms of schizophrenia. The company aims to deliver bet... Read More
